首页> 美国卫生研究院文献>Journal of Carcinogenesis >Hope for progress after 40 years of futility? Novel approaches in the treatment of advanced stage III and IV non-small-cell-lung cancer: Stereotactic body radiation therapy mediastinal lymphadenectomy and novel systemic therapy
【2h】

Hope for progress after 40 years of futility? Novel approaches in the treatment of advanced stage III and IV non-small-cell-lung cancer: Stereotactic body radiation therapy mediastinal lymphadenectomy and novel systemic therapy

机译:希望在徒劳40年后取得进步?治疗晚期III和IV期非小细胞肺癌的新方法:立体定向放射疗法纵隔淋巴结清扫术和新型全身治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality. The majority of patients present with advanced (stage III-IV) disease. Such patients are treated with a variety of therapies including surgery, radiation, and chemotherapy. Despite decades of work, however, overall survival in this group has been resistant to any substantial improvement. This review briefly details the evolution to the current standard of care for advanced NSCLC, advances in systemic therapy, and novel techniques (stereotactic body radiation therapy [SBRT], and transcervical extended mediastinal lymphadenectomy [TEMLA] or video-assisted mediastinal lymphadenectomy [VAMLA]) that have been used in localized NSCLC. The utility of these techniques in advanced stage therapy and potential methods of combining these novel techniques with systemic therapy to improve survival are discussed.
机译:非小细胞肺癌(NSCLC)仍然是癌症死亡率的主要原因。大多数患者患有晚期(III-IV期)疾病。此类患者可通过多种疗法进行治疗,包括手术,放射线和化学疗法。尽管进行了数十年的工作,但是,该组的总体存活率一直没有任何实质性的改善。这篇综述简要介绍了晚期非小细胞肺癌的最新治疗标准,全身治疗的进展以及新技术(立体定向放射治疗[SBRT]和宫颈宫颈纵隔淋巴结清扫术[TEMLA]或电视辅助纵隔淋巴结清扫术[VAMLA] )已在本地NSCLC中使用。讨论了这些技术在晚期治疗中的实用性以及将这些新技术与全身治疗相结合以提高生存率的潜在方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号